RARE - Ultragenyx Pharmaceutical Inc.
| Previous Close | 60.24 |
| Open | 60.68 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 59.21 - 61.47 |
| 52 Week Range | 37.44 - 90.98 |
| Volume | 269,632 |
| Avg. Volume | 466,940 |
| Market Cap | 3.462B |
| Beta (3Y Monthly) | 3.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- American City Business Journals•2 days ago
Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more
The future of California's stem cell research funding agency is in doubt, but its impact goes far beyond the billions of dollars it has doled out to researchers, says the Glaucoma Research Foundation.
- Zacks•6 days ago
Ultragenyx & Arcturus Therapeutics Expand Existing Agreement
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
- Insider Monkey•7 days ago
Here’s What Hedge Funds Think About Ultragenyx Pharmaceutical Inc (RARE)
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
- Markit•8 days ago
See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RAREView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for RARE with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding RARE are favorable, with net inflows of $2.65 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- American City Business Journals•15 days ago
'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases
Emil Kakkis launched Ultragenyx Pharmaceutical in Novato and the EveryLife Foundation for Rare Diseases, lobbying for legislative changes to make it easier to develop rare disease drugs.
- Zacks•21 days ago
Ultragenyx (RARE) Down 5.7% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.•last month
Is Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Paid At A Competitive Rate?
In 2010 Emil Kakkis was appointed CEO of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). This analysis aims first to...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of RARE earnings conference call or presentation 6-May-19 9:00pm GMT
Q1 2019 Ultragenyx Pharmaceutical Inc Earnings Call
- Zacks•2 months ago
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1
Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.
Motley Fool•2 months agoUltragenyx Pharmaceutical Inc (RARE) Q1 2019 Earnings Call Transcript
RARE earnings call for the period ending March 31, 2019.
- Associated Press•2 months ago
Ultragenyx: 1Q Earnings Snapshot
The Novato, California-based company said it had a loss of $1.82 per share. The results did not meet Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ...
- Zacks•2 months ago
What's in Store for Catalyst Pharma (CPRX) Q1 Earnings?
Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.
- Zacks•2 months ago
Factors Expected to Influence Qorvo (QRVO) in Q4 Earnings
Qorvo's (QRVO) expanding portfolio of 5G and GaN solutions hold promise.
- Zacks•2 months ago
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.
- Insider Monkey•2 months ago
Did Hedge Funds Drop The Ball On Ultragenyx Pharmaceutical Inc (RARE) ?
Legendary investors such as Jeffrey Talpins and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don't publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That's why we analyze the […]
- Zacks•2 months ago
Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?
Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results
- Zacks•2 months ago
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•2 months ago
5 Biotech Stocks Defying the Medicare-for-All Scare
Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.
- American City Business Journals•2 months ago
Health Care Digest: Attacking a deadly infant virus, Medicaid's smoking gun and exporting genetic expertise
This week's Health Care Digest explores growing companies and introduces our new health care reporter, Hannah Norman.
- Zacks•2 months ago
Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA
Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.
- Zacks•3 months ago
Global X Launches GNOM ETF to Tap Booming Genomics Space
Having exposure to trending areas like Robotics & AI, e-commerce and IoT, Global X is set to gain from the booming genomics market with the GNOM ETF.
